β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-30

Study Completion Date

2019-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Epidermal Growth Factor Receptor tyrosine-kinase inhibitors （EGFR-TKIs）, including gefitinib，erlotinib and icotinib demonstrate excellent effect on the treatment of non small cell lung cancer (NSCLC) patients with EGFR mutations. However, patients who are initially sensitive to the drugs eventually become resistance. In this study, the investigators aim to explore the efficacy of beta-elemene, combining with EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer

NCT03461185

Non Small Cell Lung Cancer

UNKNOWN PHASE2

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

NCT03544814

Lung Adenocarcinoma EGFR Activating Mutation

COMPLETED PHASE2

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study

NCT04401059

Carcinoma Non-Small-Cell Lung Cancer Adenocarcinoma

RECRUITING PHASE4

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study

NCT04397432

Carcinoma, Non-Small-Cell Lung

ACTIVE_NOT_RECRUITING

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

NCT06300424

Non Small Cell Lung Cancer EGFR Gene Mutation

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib，erlotinib and icotinib demonstrate excellent effect on the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, patients who are initially sensitive to the drugs eventually become resistance. Beta-elemene, a natural plant drug extracted from Curcuma wenyujin, has been used as an antitumor drug for different tumors, including NSCLC via mechanism that inhibits Ras/Mapk signaling and cell cycle progression.In this study, the investigators aim to explore the efficacy of beta-elemene, combining with EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance.

main objectives: progression-free survival (PFS) ratio in 12 week the secondary goal: Objective Response Rate （ORR）

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

β-elemene+EGFR TKI

EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) and β-elemene

Group Type EXPERIMENTAL

β-elemene

Intervention Type DRUG

β-elemene：400-600mg + 5%GS 500ml,ivgtt,qd, continuously 45days

EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)

Intervention Type DRUG

EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual

EGFR TKI

EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)

Group Type ACTIVE_COMPARATOR

EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)

Intervention Type DRUG

EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

β-elemene

β-elemene：400-600mg + 5%GS 500ml,ivgtt,qd, continuously 45days

Intervention Type DRUG

EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)

EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

elemene liposomes

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Obtain of informed consent.
2. Histologically or cytologically confirmed, inoperable, recurrence or metastasis advanced non-small cell lung cancer (TNM Stage ⅢB or stage Ⅳ), took EGFR-TKI longer than 6 months and appeared disease progression.
3. At least one measurable lesion (helical CT scan long diameter ≥10mm, meet the requirements of the standard Response Evaluation Criteria In Solid Tumors（RESCIST） version 1.1).
4. Eastern Cooperative Oncology Group（ECOG）Performance Status（PS） :0-2.
5. Aged from 18 to 75 years (18 and 75 years are included).
6. Life expectancy ≥12 weeks.
7. Adequate bone marrow reserve and organ function as follows:

Absolute neutrophils count (ANC) ≥1.5 x 10 to the 9th power/L (band neutrophil and segmented neutrophil), platelets \> 100 x 10 to the 9th power/L and Hb≥90g/L.

Hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (ULN).

Alkaline phosphatase (AP), alanine transaminase (ALT) and aspartate transaminase (AST) less than or equal to 3.0 times ULN (or less than or equal to 5 times ULN in case of known liver involvement.

Renal: Serum Creatinine less than or equal to 1.25 times upper limit of normal (ULN).
8. Females of child-bearing potential must have negative serum pregnancy test. Sexually active males and females (of childbearing potential) willing to practice contraception during the study.

Exclusion Criteria

1. Do not meet the above criteria.
2. Unhealed toxicity of prior anti-cancer treatment (CTCAE Level 1) or surgery.
3. Symptomatic Central Nervous System (CNS) metastases.
4. Clinical uncontrolled active infection, such as acute pneumonia, active hepatitis B or C (prior hepatitis B history, despite medication treatment control or not, HBV DNA≥500copies or ≥100IU/ml), etc.
5. Prior other malignant disease in 5 years (except carcinoma in situ of cervix, or non melanoma skin cancers, or localized prostate cancer with Gleason ≤6).
6. Take part in new drug clinical trials within one month or taking part in a trial now.
7. Pregnant or lactating woman.
8. Other conditions regimented at investigators' discretion.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No